Takeda Pharmaceutical (TKPHF) EBIT Margin (2017 - 2026)

Takeda Pharmaceutical's EBIT Margin history runs 10 years deep, the most recent figure standing at 1.24% for Q1 2026.

• In Q1 2026, EBIT Margin fell 3289.0% year-over-year to 1.24%; the TTM figure through Mar 2026 stood at 22.49% (down 252.0% YoY), while the FY2026 annual figure was 9.07%, up 159.0% from the prior year.
• EBIT Margin was 1.24% for Q1 2026 at Takeda Pharmaceutical, down from 18.36% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 31.65% in Q1 2025 to a low of 1.24% in Q1 2026.
• Historically, EBIT Margin has averaged 18.47% across 5 years, with a median of 18.0% in 2024.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin soared 3261 bps in 2025, then slumped 3289 bps in 2026.
• A 5-year view of EBIT Margin shows it stood at 13.4% in 2022, then surged by 66 bps to 22.24% in 2023, then dropped by 19 bps to 18.0% in 2024, then advanced by 2 bps to 18.36% in 2025, then plunged by 107 bps to 1.24% in 2026.
• The last three EBIT Margin figures came in at 1.24% (Q1 2026), 18.36% (Q4 2025), and 28.52% (Q3 2025), per Business Quant data.